

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)

Taiji Sakamoto, Masahiko Shimura, Shigehiko Kitano, Masahito Ohji, Yuichiro Ogura, Hidetoshi Yamashita, Makoto Suzaki, Kimie Mori, Yohei Ohashi, Poh Sin Yap, Takeumi Kaneko, Tatsuro Ishibashi, for the MERCURY Study Group

Corresponding author:

Taiji Sakamoto

Department of Ophthalmology, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan

Tel: +81 99-275-5402

Fax: +81 99-265-4894

Email: tsakamot@m3.kufm.kagoshima-u.ac.jp

Online Resource 11. Correlation between number of anti-VEGF injections for both eyes from baseline to month 11 and change in HADS score from baseline to month 12 (safety set^a). **a:** HADS-A score; **b:** HADS-D score

Bubble sizes represent the number of patients. Pearson's correlation coefficient (*r*) and corresponding *p* values are presented.

^aFor patients with evaluable data at baseline and Month 12.

HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; VEGF, vascular endothelial growth factor.

